Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical Co. announced the completion of a share buyback, repurchasing 153,400 common shares for 232,930,350 yen between November 1 and November 5, 2025. This move is part of a broader strategy approved by the Board of Directors to repurchase up to 19.8 million shares, representing 5.8% of the total shares outstanding, with the aim of enhancing shareholder value and optimizing capital structure.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1688.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals worldwide. With over 130 years of experience, Santen is involved in global research, development, manufacturing, and sales of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,518,848
Technical Sentiment Signal: Buy
Current Market Cap: Yen520.3B
Find detailed analytics on 4536 stock on TipRanks’ Stock Analysis page.